ArticleMolecular and cellular biology1998
A short sequence within two purine-rich enhancers determines 5' splice site specificity.
Article in Molecular and cellular biology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- PLP/DM20 ratio is regulated by hnRNPH and F and a novel G-rich enhancer in oligodendrocytes.Nucleic acids research · 2007Article
- Enhancer-dependent 5'-splice site control of fruitless pre-mRNA splicing.The Journal of biological chemistry · 2003Article
- SRp30c is a repressor of 3' splice site utilization.Molecular and cellular biology · 2002Article
- Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion.The Journal of biological chemistry · 2001Article
- The sequence complementarity between HIV-1 5' splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA.RNA (New York, N.Y.) · 2001Article
- Splicing of constitutive upstream introns is essential for the recognition of intra-exonic suboptimal splice sites in the thrombopoietin gene.Nucleic acids research · 2001Article
- An intronic splicing enhancer binds U1 snRNPs to enhance splicing and select 5' splice sites.Molecular and cellular biology · 2000Article
- Selection of alternative 5' splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1.Molecular and cellular biology · 2000Article
- Control of hnRNP A1 alternative splicing: an intron element represses use of the common 3' splice site.Molecular and cellular biology · 2000Article
- Identification of a bidirectional splicing enhancer: differential involvement of SR proteins in 5' or 3' splice site activation.Molecular and cellular biology · 1999Article
- Antagonism between RSF1 and SR proteins for both splice-site recognition in vitro and Drosophila development.Genes & development · 1999Article
- Selection and characterization of pre-mRNA splicing enhancers: identification of novel SR protein-specific enhancer sequences.Molecular and cellular biology · 1999Article
- The splicing factors 9G8 and SRp20 transactivate splicing through different and specific enhancers.RNA (New York, N.Y.) · 1999Article
- Donor site competition is involved in the regulation of alternative splicing of the rat beta-tropomyosin pre-mRNA.RNA (New York, N.Y.) · 1999Article
- Enhancer elements activate the weak 3' splice site of alpha-tropomyosin exon 2.RNA (New York, N.Y.) · 1998Article
- Muscle-specific splicing of a heterologous exon mediated by a single muscle-specific splicing enhancer from the cardiac troponin T gene.Molecular and cellular biology · 1998Article
- An RNA splicing enhancer-like sequence is a component of a splicing inhibitor element from Rous sarcoma virus.Molecular and cellular biology · 1998Article
- Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression.Journal of biomedical scienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purine-rich enhancers are exon sequences that promote inclusion of alternative exons, usually via activation of weak upstream 3' splice sites. A recently described purine-rich enhancer from the caldesmon gene has an additional activity by which it directs selection of competing 5' splice sites within an alternative exon. In this study, we have compared the caldesmon enhancer with another purine-rich enhancer from the chicken cardiac troponin T (cTNT) gene for the ability to regulate flanking splice sites. Although similar in sequence and length, the two enhancers demonstrated strikingly different specificities towards 5' splice site choice when placed between competing 5' splice sites in an internal exon. The 32-nucleotide caldesmon enhancer caused effective usage of the exon-internal 5' splice site, whereas the 30-nucleotide cTNT enhancer caused effective usage of the exon-terminal 5' splice site. Both enhancer-mediated splicing pathways represented modulation of the default pathway in which both 5' splice sites were utilized. Each enhancer is multipartite, consisting of two purine-rich sequences of a simple (GAR)n repeat interdigitated with two enhancer-specific sequences. The entire enhancer was necessary for maximal splice site selectivity; however, a 5- to 7-nucleotide region from the 3' end of each enhancer dictated splice site selectivity. Mutations that interchanged this short region of the two enhancers switched specificity. The portion of the cTNT enhancer determinative for 5' splice site selectivity was different than that shown to be maximally important for activation of a 3' splice site, suggesting that enhancer environment can have a major impact on activity. These results are the first indication that individual purine-rich enhancers can differentiate between flanking splice sites. Furthermore, localization of the specificity of splice site choice to a short region within both enhancers indicates that subtle differences in enhancer sequence can have profound effects on the splicing pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.